09 April 2019 | News
A. Menarini Diagnostics will perform sales, marketing, training, and customer support for the WaveForm CGM
WaveForm Technologies Inc. a wholly owned subsidiary of AgaMatrix Holdings LLC and developer of novel products for continuous glucose monitoring, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, recently announced a partnership to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM).
The innovative WaveForm CGM was specifically chosen to integrate within A. Menarini Diagnostics' connected diabetes care platform. According to the agreement, A. Menarini Diagnostics will perform sales, marketing, training, and customer support for the WaveForm CGM in a long term partnership in territories throughout EMEA and LATAM.
The WaveForm CGM system is based on several pioneering, patented innovations in glucose sensor technology, facilitating a virtually pain-free insertion process, limited interferences, and extended wear time. This agreement establishes the first wave of distribution for the WaveForm CGM system and international commercialization, following WaveForm's anticipated CE clearance in 2019.
In addition, A. Menarini Diagnostics S.r.l. and AgaMatrix Holdings LLC, are discussing terms to commercialize a Bluetooth® enabled blood glucose monitor and future enhancements to the WaveForm CGM.